Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Beijing Biostar Pharmaceuticals Co., Ltd. Class H ( (HK:2563) ) is now available.
Beijing Biostar Pharmaceuticals Co., Ltd. announced a proposed change of auditor, with Daxin Global (HK) CPA Limited set to retire after the upcoming annual general meeting in August 2025. The company plans to switch its offshore financial statements from HKFRS to China Accounting Standards for Business Enterprises starting in 2025, prompting the appointment of WUYIGE Certified Public Accountants LLP as the new auditor. This change aims to align financial disclosure standards between the PRC and Hong Kong markets, potentially impacting stakeholders by ensuring more consistent and transparent financial reporting.
More about Beijing Biostar Pharmaceuticals Co., Ltd. Class H
Beijing Biostar Pharmaceuticals Co., Ltd. is a joint stock company incorporated in China, operating in the pharmaceutical industry. The company focuses on the development and production of biopharmaceutical products, serving both domestic and international markets.
Average Trading Volume: 1,140,900
Technical Sentiment Signal: Hold
See more data about 2563 stock on TipRanks’ Stock Analysis page.